We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Therapy Techniques Contributed to a Decrease in Cancer Rates

By Biotechdaily staff writers
Posted on 06 Nov 2007
Professional radiology societies in the United States are encouraged by a recent report that credits improved screening techniques and more effective treatment for the noticeable decline in U.S. More...
cancer mortality rates.

The American College of Radiology (ACR; Reston, VA, USA), through its clinical trials research groups, the American College of Radiology Imaging Network (ACRIN) and the Radiation Therapy Oncology Group (RTOG), has conducted research in diagnostic imaging and radiation therapy for nearly 40 years and is one of the largest National Cancer Institute- (NCI)-funded clinical research organizations in the country.

The report, called Annual Report to the Nation on the Status of Cancer, was created by the American Cancer Society, the U.S. Centers for Disease Control and Prevention, the U.S. National Cancer Institute, and the North American Association of Central Cancer Registries.

"The ACR is proud of the research coordinated by our cooperative groups and by other institutions nationwide,” said Arl Van Moore, Jr., M.D., FACR, chair of the ACR Board of Chancellors. "We are pleased that these types of research are leading to better diagnostic and radiation therapy techniques, which can help to improve disease detection, and save and extend lives.”

Recently, the ACR launched ACR Image Metrix, a contract research organization, which assists pharmaceutical and biotech manufacturers in the anticancer drug development using cutting-edge imaging to assist in the more rapid assessment of new anticancer compounds. "We are very encouraged by this recent report on the drop in cancer deaths and believe that the rapidly-expanding imaging technology and techniques for drug development will only continue to accelerate more anticancer drugs onto the market,” said Mike Morales, general manager for ACR Image Metrix.

The ACR's clinical research programs are among the largest recipients of U.S. medical research grants, and have an established reputation for handling large-scale clinical trials, involving up to 50,000 patients and the processing of some 50 million images. ACR Image Metrix will utilize the same infrastructure and expertise, but will provide support to pharmaceutical firms, biotechnology companies, and medical device manufacturers seeking U.S. Food and Drug Administration approval to bring new drugs, therapies, and medical devices to market.


Related Links:
American College of Radiology
ACR Image Metrix

New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
POC Immunoassay Analyzer
Procise DX
New
Automatic CLIA Analyzer
Shine i6000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Plasma pTau217 testing can predict future amyloid accumulation and cognitive decline in cognitively healthy older adults (photo courtesy of Shutterstock)

Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms

Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more

Industry

view channel
Image: Pathlight combines WGS and dPCR to identify and longitudinally track large‑scale genomic changes, known as structural variants (photo courtesy of SAGA Diagnositcs)

Roche Affiliate Expands MRD Portfolio with SAGA Acquisition

Foundation Medicine, Inc., an independent affiliate of Roche, announced plans to expand its monitoring portfolio with SAGA Diagnostics’ Pathlight, a personalized, tumor-informed molecular residual disease... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.